The first clinical trial of the BBB Trojan horse technology tested the effects of a fusion protein of the chimeric HIRMAb, and L-α-iduronidase (IDUA), the lysosomal enzyme mutated in Mucopolysaccharidosis Type I (MPSI). Here, IDUA is linked to mucopolysaccharidosis type 1.